The Bloodless Surgery Consult for the Overworked Fellow

The pager goes off. The message reads: “Bloodless surgery consult — patient refusing blood products.” If you are a transfusion medicine fellow and this is your first one, you probably spend a moment staring at your pager wondering exactly what you are supposed to do with that information.

You show up, introduce yourself, and are handed a form. It is several pages long. At the top, in clear block letters: WHOLE BLOOD COMPONENTS. Below that, a list of products — red blood cells, platelets, plasma — each followed by two checkboxes. Accept. Reject.

It seems simple enough. Then you keep reading.

By the time you reach plasma protein fractions, recombinant clotting factors, and thrombopoietin mimetics, you realize this is not a simple form. It is a document that asks a person to think, in advance and in detail, about exactly how much of their own blood — and everyone else’s — they are willing to accept back into their body under duress. The checkboxes are tidy. The clinical reality underneath them is not.

Why This Consult Exists

The most common reason you will encounter a bloodless surgery consult is a patient who is a Jehovah’s Witness. Members of this faith generally decline transfusion of whole blood and its four primary components — red blood cells, white blood cells, platelets, and plasma — based on a religious interpretation of scriptural passages prohibiting the “taking in” of blood. But the boundaries of that refusal are personal, not prescribed. Individual Jehovah’s Witnesses vary significantly in what they will and will not accept, which is precisely why the form exists and why the consult matters.

Not every patient requesting bloodless or transfusion-free care is a Jehovah’s Witness. Some patients have religious objections that are less formalized. Others have philosophical objections to allogeneic blood, concerns about transfusion-transmitted infections, or simply a strong preference to avoid a product they view as high-risk. The label “bloodless surgery” is something of a misnomer — the goal is not zero blood, but zero allogeneic blood. Whether that is achievable depends on the clinical situation, the alternatives available, and what the patient has actually agreed to.

The form is the tool that documents that agreement. The conversation is the actual work.

The Form, Decoded

Walk through the major product categories and the clinical stakes become clearer.

Whole blood components — red cells, platelets, plasma, white cells — are the straightforward part. Most patients who have thought carefully about this have already made their decision about these products before you walk in the room. These are the checkboxes they came prepared for.

Plasma fractions are where things get philosophically interesting. Albumin is derived from pooled human plasma, fractionated, and heat-treated. Cryoprecipitate is thawed plasma precipitate, rich in fibrinogen and factor VIII. Fresh frozen plasma is essentially unfractionated. A patient might accept albumin but decline FFP, not because they are being inconsistent, but because fractionation changes the product enough to matter to them, even if it does not particularly change the clinical calculus for you. This is not a contradiction you are there to resolve. It is a distinction you are there to understand and document.

Autologous techniques — cell saver, acute normovolemic hemodilution, apheresis, dialysis — occupy a fascinating middle ground. Many patients who decline allogeneic blood are entirely comfortable with their own blood being collected, processed through a machine, and returned to them, as long as the circuit remains closed and continuous. The blood never “leaves” them in any meaningful sense. Practically, this means cell saver is often on the table even when packed red blood cells are not, and that distinction matters enormously in a surgical or hemorrhage scenario.

Erythropoiesis-stimulating agents, colony-stimulating factors, and thrombopoietin mimetics round out the list. These are pharmacologic scaffolds — tools to build up what the patient has before a major procedure, or to support recovery after one. Some formulations contain albumin as a stabilizer. For some patients, that matters. For others, it does not. You need to know which.

The Grey Area Nobody Warns You About: Plasma-Derived Clotting Factors

Here is something the form does not make obvious, and that fellows often do not realize until they are standing at the bedside: several of the products in the “clotting factors” section are derived from pooled human plasma.

Kcentra — the four-factor prothrombin complex concentrate most of us reach for in warfarin reversal or urgent coagulopathy — is plasma-derived. So is Riastap, the fibrinogen concentrate. Humate-P, which contains both factor VIII and von Willebrand factor, is plasma-derived. These are not recombinant products engineered in a lab. They are fractionated from pooled donor plasma, processed and pathogen-reduced, but fundamentally the same source material as fresh frozen plasma. The processing is different. The origin is not.

A brief detour into hemophilia is useful here, because the recombinant versus plasma-derived distinction has a history that most fellows outside of hematology do not fully appreciate. For most of the twentieth century, factor VIII and factor IX concentrates used to treat hemophilia A and B were plasma-derived — pooled from thousands of donors, with all the viral risk that entailed. The consequences in the 1980s were devastating: contaminated plasma-derived concentrates transmitted HIV and hepatitis C to a substantial portion of the hemophilia population before adequate screening and viral inactivation methods existed. That disaster drove the development of recombinant factor products, which began reaching the market in the early 1990s. Today, recombinant factor VIII and factor IX concentrates — including extended half-life versions — are the standard of care for hemophilia in high-income settings. Plasma-derived equivalents still exist and are still used, particularly where recombinant products are less accessible, and in conditions like von Willebrand disease where a plasma-derived product containing both factor VIII and vWF is sometimes preferred. But the field has largely moved on.

The relevance for bloodless surgery is this: the products you are most likely to reach for in an acute coagulopathy — Kcentra, Riastap — do not yet have widely available recombinant equivalents. A recombinant fibrinogen concentrate exists in development but is not in routine clinical use. So unlike hemophilia care, which has largely transitioned away from plasma-derived products, the hemostatic toolkit for your typical bleeding surgical patient is still substantially plasma-derived. That gap matters when your patient has declined plasma.

Where recombinant options do exist, they matter a great deal. Recombinant factor VIIa (NovoSeven) is produced in baby hamster kidney cells — no human plasma involved. Recombinant factor VIII and factor IX are similarly plasma-free. For a patient whose objection extends to all human blood fractions, these products may be acceptable where plasma-derived concentrates are not. The reverse can also be true: some patients are comfortable with highly processed plasma fractions but draw the line at whole plasma or red cells. You cannot predict which way a given patient will land. The form gives you a framework. The conversation gives you the actual answer.

This is one of the more uncomfortable aspects of bloodless surgery medicine: the fellow’s job is not just to document preferences, but to ensure those preferences are genuinely informed. That means being willing to say, politely and clearly, “I want to make sure you know that this product comes from human plasma — is that still acceptable to you?” Most patients appreciate it. Some are surprised. Occasionally, it changes their answer. All of those outcomes are better than the alternative.

When the Checkboxes Run Out

The form creates legal clarity. It does not always create clinical clarity.

Consider a patient who has accepted cell saver but declined cryoprecipitate. Intraoperatively, they develop a coagulopathy. The surgeons look at you. The anesthesiologist looks at you. The patient is not in a position to revisit their checklist. You are not there to override their documented wishes — you are there to help the team understand what options remain, and what their limits are.

In practice, this means knowing your alternatives well enough to deploy them quickly. Can you correct a fibrinogen deficit with a fibrinogen concentrate the patient has accepted? What is the hemostatic ceiling of topical procoagulants like fibrin sealants? Is the surgical team using electrocautery aggressively enough? Is there an interventional radiology option? The transfusion medicine fellow in the bloodless surgery consult is not just a documentarian. You are a consultant in the truest sense — someone whose job is to expand the team’s range of options, not just to manage their expectations.

And then there are the cases where the options run out. Where the patient is bleeding and the only thing that would reliably help is a product they have refused. You learn to sit with that. You learn that informed refusal is not a failure of medicine. You learn that the consult you did beforehand — the one where you made sure the patient understood exactly what they were declining, and why, and what the alternatives were — was the most important one.

What These Consults Teach You

Bloodless surgery consults are a masterclass in what blood products actually do. Because you cannot default to transfusion, you have to explain — to the patient, to the team, and to yourself — exactly what each product is for, what happens physiologically without it, and what can plausibly substitute. You will leave your first few of these consults knowing your coagulation cascade better than you did going in. That is an underappreciated upside.

You also learn something about the nature of consent itself. Most informed consent in medicine is procedural: sign here, you understand the risks. Bloodless surgery consent is longitudinal. It happens before the procedure, often well before, and it asks the patient to project themselves into scenarios they cannot fully anticipate. It demands that you, as the consultant, be honest about uncertainty — about what the surgery might require, about which alternatives are genuinely equivalent and which are merely adjacent.

Accept or Reject

The form implies a binary. Accept. Reject. Medicine is almost never that clean.

The most useful thing I can tell a fellow going into their first bloodless surgery consult is this: the form is not the point. The point is the conversation that produces it — the one where you find out what the patient actually believes, what they actually understand, and what they are actually willing to accept when the stakes become real. The checkboxes are documentation. The consult is medicine.

And if you leave that room feeling like you understood it completely, you probably missed something.